Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/07/微信截图_20240619143131.jpg)
What are the adverse reactions after CAR-T cell reinfusion?
Interpretation of Hot Topics Conerning Mutiple Myeloma Patients:![💐](https://static.xx.fbcdn.net/images/emoji.php/v9/te3/1/16/1f490.png)
“What are the adverse reactions after CAR-T cell reinfusion?”![🌹](https://static.xx.fbcdn.net/images/emoji.php/v9/t71/1/16/1f339.png)
Process Diagram for Myeloma Patients Receiving CAR-T Therapy
RRMM(Relapsed/Refractory Multiple Myeloma)
Unveiling how the “million-dollar anti-cancer shot” saves patients with recurrent and refractory bone tumors! Taking you through the entire process of CAR-T therapy.
CAR-T细胞回输后有哪些不良反应?![🌺](https://static.xx.fbcdn.net/images/emoji.php/v9/t99/1/16/1f33a.png)
骨髓瘤患者接受CAR-T治疗的流程图
权威专家解读之骨髓瘤全程管理
Expert Introduction
![👩🔬](https://static.xx.fbcdn.net/images/emoji.php/v9/tea/1/16/1f469_200d_1f52c.png)
Chief Phsician Professor Doctoral Supervisor
Peking University People’s Hospital,
Peking University Institute of Hematology
Director-General and Standing Committee of Hematolog Branch of Chinese Phsicians Association
Memer of the International Meloma oring Group Asia-Pacific Meloma oring Group
Associate Leader Plasma Ctolog Group Hematolog Branch Chinese Medical Association
Memer of the China and International Collaorative Group on Primar Sstemic Amloidosis
President of Hematologists Branch of Beiing Phsicians Association
Memer of International Research Group on Renal and Monoclonal lmmunogloulinopathies
Vice President of Hematolog Branch of Chinese Geriatrics Association and Chairman of Academic Commitee on Muliple Meloma
Associate Leader Multiple Meloma and Related Diseases Group Hematolog Committee Chinese Association of Female Phsicians
![🎉](https://static.xx.fbcdn.net/images/emoji.php/v9/t8c/1/16/1f389.png)
To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#CART #Mutiplemyeloma #carttherapy #myeloma #leukemia #drug #RRMM #cancer #cancertreatment #tcell #cell #advancedmedical #AdvancedMedicineinChina
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/06/微信截图_20240624180545.jpg)
The Hidden “Anti-Cancer Weapon” in Tumor Tissue – TIL Cells
### The Hidden “Anti-Cancer Weapon” in Tumor Tissue – TIL Cells
![TIL Therapy](https://www.medtourcn.com/wp-content/uploads/2024/06/微信截图_20240624180545.jpg)
TIL Therapy
**TIL Cells: Turning Tumor Tissue “Waste” into Treasure**
Lymphocytes are a crucial part of the immune system. They can be found both in the periphery and within tumor tissues, serving as the body’s natural defense against tumor cells. Traditionally, only a small portion of excised tumor tissue is used for pathological diagnosis, while the majority is discarded as medical waste. This practice wastes the valuable anti-cancer resources hidden within the patient’s own body!
Tumor-Infiltrating Lymphocyte (TIL) therapy involves extracting lymphocytes from the tumor biopsy tissue of cancer patients. Using DNA sequencing technology, these lymphocytes surrounding the tumor cells are collected, expanded, and cultured in vitro before being reinfused into the patient. TIL therapy has shown positive clinical outcomes in various solid tumors, such as non-small cell lung cancer, melanoma, colorectal cancer, ovarian cancer, cervical cancer, and head and neck cancers. Compared to other T-cell therapies like CAR-T and TCR-T, TIL therapy offers broader targeting, more precise recognition, and more enduring anti-cancer effects.
**Applications of TIL Cells**
1. **For Early-Stage Cancer Patients:** TIL cells can be used as adjuvant therapy after surgery, helping to eliminate residual cancer cells following traditional treatments like surgery, radiotherapy, and chemotherapy, thereby preventing tumor recurrence or metastasis.
2. **For Advanced Cancer Patients:** TIL cells can serve as a last-line salvage treatment, aiding in extending survival time, improving quality of life, and addressing the dilemma of “no available drugs” for late-stage cancer patients.
**The Relationship Between TIL Cells and Cancer Patient Prognosis**
Using “non-small cell lung cancer” (#NSCLC) as an example, we can explore the impact of peripheral and tumor-infiltrating lymphocytes (TIL cells) on the prognosis of cancer patients.
A hospital in Tianjin, China, collected peripheral blood and tumor tissue samples from 105 newly diagnosed and untreated stage III/IV NSCLC patients. They analyzed the overall composition of peripheral blood cells and TIL cells, calculating and analyzing the overall survival (OS) of all patients. The results were as follows:
1. The median overall survival (mOS) for all patients was 12 months. The 1-year, 2-year, and 3-year overall survival (OS) rates were 60.5%, 28.4%, and 18.6%, respectively.
2. Patient OS was related to tumor size, tumor pathology, and CRP levels.
– **Tumor Size:** Patients with tumor lesions smaller than 4.8 cm had significantly longer OS compared to those with lesions larger than 4.8 cm (p=0.040).
– **Tumor Pathology:** Patients with squamous cell carcinoma had significantly longer OS compared to those with adenocarcinoma (p=0.025).
– **CRP Levels:** Patients with CRP levels below 8.29 mg/L had significantly longer OS compared to those with higher CRP levels (p=0.011).
– **Tumor CD4+ and CD8+ T Cell Infiltration:** Patients with higher levels of tumor CD4+ and CD8+ T cell infiltration had significantly longer survival compared to those with lower infiltration levels (p<0.0001 and p=0.011, respectively).
In conclusion, in newly diagnosed stage III/IV NSCLC patients, OS is associated with increased numbers of peripheral lymphocytes, CD4+ TIL, and CD8+ TIL, and is positively correlated with several basic clinical factors. This highlights the necessity of timely TIL cell storage. Patients are advised not to waste their valuable anti-cancer immune cells.
**Timing of TIL Cell Storage**
Generally, TIL cells should be stored as early as possible, ideally before receiving other treatments like radiotherapy or chemotherapy. At this stage, TIL cells have the strongest anti-cancer capability for the following reasons:
1. **TIL Cell Quantity:** TIL cell numbers gradually decrease as the tumor progresses. Clinical studies on TIL cell therapy for melanoma have found that T cell and NK cell numbers significantly decrease with tumor progression.
2. **Postoperative Adjuvant Radiotherapy and Chemotherapy:** These treatments not only kill cancer cells but also destroy immune cells and normal cells, reducing the anti-cancer efficacy of immune cells. Clinical studies on TIL cell therapy for cervical cancer have shown that CD4+ and CD8+ cell numbers significantly decrease in late-stage tumor TIL cells.
Therefore, patients are encouraged to seize their precious and unique opportunity for anti-cancer treatment. With the consent of their primary physician, they should preserve fresh tumor tissue samples preoperatively and entrust professional institutions with TIL cell isolation, culture, and cryopreservation. This can be used for postoperative adjuvant therapy to eliminate residual cancer cells, prevent tumor recurrence, or serve as a last-line salvage treatment for advanced cancer patients.
Since its initial clinical application in 1988, TIL therapy has developed over more than thirty years. Compared to other T-cell therapies, TIL therapy has the unique advantage of turning the patient’s own tumor tissue “waste” into a valuable resource, offering unique benefits in treating solid tumors and even helping some patients achieve long-term survival with the tumor.
China’s TIL therapy has been specially modified based on the American tumor-infiltrating lymphocyte (TIL) therapy to enhance TIL cell self-expansion ability and overcome the tumor microenvironment. In recent years, several new TIL therapies have been developed in China. Notably, the two TIL therapies showcased at the 2024 ASCO conference not only demonstrated impressive efficacy but also featured one therapy that requires neither lymphodepletion nor IL-2 treatment, significantly improving safety and cost-effectiveness!
The good news is that several TIL therapies have been officially approved for clinical research in China, targeting various solid tumors such as non-small cell lung cancer, cholangiocarcinoma, esophageal cancer, cervical cancer, ovarian cancer, and breast cancer. Patients seeking to store tumor tissue or seek TIL therapy assistance can consult Advanced Medicine in China
WhatsApp: 137 1795 9070
Email: doctor.huang@globecancer.com
#til #tilcell #cancer #nonsmallcelllungcancer #cholangiocarcinoma #carcinoma #esophagealcancer #cervicalcancer #ovariancancer #breastcancer #tumor #Tiltherapy #ASCO #asco2024 #2024asco
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/06/微信截图_20240613110236.jpg)
Interpretation of Hot Topics Conerning Relapsed/Refractory Mutiple Myeloma Patients
Interpretation of Hot Topics Conerning Relapsed/Refractory Mutiple Myeloma Patients:![💐](https://static.xx.fbcdn.net/images/emoji.php/v9/te3/1/16/1f490.png)
What other treatment options are available for patients with relapsed Multiple Myeloma?
How effective is the new drug treatment for the first relapse of Multiple Myeloma?
What treatment options are available for initial relapse of multiple myeloma?
What are the treatment goals for Relapsed/Refractory Multiple Myeloma (RRMM)?
What treatment strategy should be adopted for RRMM in order to achieve maximum relief?
For Relapsed/Refractory Multiple Myeloma, what are the Grades of Response?
Expert Introduction
👩🔬Zhuang Junling
Associate Chief Physician Department of Hematology
Peking Union Medical College Hospital
Published over 50 papers in journals such as Blood, Leukemia Research, and others.
🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#CART #Mutiplemyeloma #CARTtherapy #myeloma #leukemia #drug #RRMM #cancer #cancersurvivor #cancerpatient #bloodcancer #tumor #cartcell #cartcelltherapy #cancertreatment #advancedmedicineinchina #hematology
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/05/微信截图_20240514165426.jpg)
Chinese Innovation in Medicine: A New Milestone in Small Cell Lung Cancer Treatment!
![🎉](https://static.xx.fbcdn.net/images/emoji.php/v9/t8c/1/16/1f389.png)
**Chinese Innovation in Medicine: A New Milestone in Small Cell Lung Cancer Treatment!**![✨](https://static.xx.fbcdn.net/images/emoji.php/v9/tf4/1/16/2728.png)
![🎉](https://static.xx.fbcdn.net/images/emoji.php/v9/t8c/1/16/1f389.png)
![Small Cell Lung Cancer](https://www.medtourcn.com/wp-content/uploads/2024/05/微信截图_20240514165426.jpg)
Small Cell Lung Cancer
In the field of medicine, each new drug represents a leap forward in disease treatment, bringing new light and hope to patients. On May 9, 2024, the highly anticipated novel PD-L1 inhibitor, Bevosubab Single Monoclonal Antibody, officially received approval from the National Medical Products Administration (#NMPA) of China! This marks a vibrant addition to the treatment options for patients with extensive-stage small cell lung cancer, adding a brilliant rainbow to the sky of treatment.
Bevosubab Single Monoclonal Antibody is a Class I innovative drug declared by the Chinese biopharmaceutical subsidiary, Sinda Pharmaceuticals, for first-line treatment of extensive-stage small cell lung cancer.
Bevosubab Single Monoclonal Antibody is extraordinary—it is a brand-new PD-L1 inhibitor that directly targets the immune escape mechanism of tumor cells, awakening the body’s immune system to eradicate cancer cells invisibly. Combined with Anlotinib Hydrochloride, Etoposide, and Carboplatin, it forms a powerful treatment alliance, bringing new hope to small cell lung cancer.
This is not just a treatment regimen, but a redemption. In the ETER701 study, this four-drug combination therapy has rewritten the history of first-line treatment for small cell lung cancer! Survival has nearly doubled, greatly increasing the chances of survival and bringing more hope to patients.
What’s even more exciting is that, while using the combination therapy, the occurrence of adverse reactions is extremely manageable. This means that while gaining a longer life span, patients do not have to overly worry about the potential negative impacts of treatment.
The approval of Bevosubab Single Monoclonal Antibody not only opens new treatment doors for patients with extensive-stage small cell lung cancer but also brings new directions for exploration in the medical field. We are full of anticipation and believe that this new drug will shine brightly in future clinical practice, bringing endless hope and vitality to more patients!
To assess whether the condition is suitable for new durg therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <#AdvancedMedicineinChina> for preliminary evaluation!
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
#SmallCellLungCancerTreatment #BevosubabSingleMonoclonalAntibody #NewDrugApproval #MedicalBreakthrough #cancer #cancertreatment #lung #lungcancer
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/04/微信截图_20240415093348.jpg)
Introducing the Momentum of the Next-Generation “Pan-Cancer” Targeted Therapy ICP-723 of China
Introducing the Momentum of the Next-Generation “Pan-Cancer” Targeted Therapy ICP-723 of China![🍀](https://static.xx.fbcdn.net/images/emoji.php/v9/te0/1.5/16/1f340.png)
![Pan-Cancer](https://www.medtourcn.com/wp-content/uploads/2024/04/微信截图_20240415093348.jpg)
Pan-Cancer
ICP-723
On April 11, 2022, InnoCare Pharma unveiled the preclinical data of ICP-723. The research results demonstrate that ICP-723 effectively inhibits the kinase activity of TRKA, TRKB, and TRKC (IC50 value less than 1 nM). Not only does ICP-723 exhibit potent in vitro efficacy in TRK-driven tumors, but it also overcomes resistance mutations commonly seen after treatment with first-generation TRK inhibitors, such as TRKA G595R and TRKC G623R/E.
TGI 89.5%
Further in vivo efficacy studies have confirmed the robust anti-tumor effect of ICP-723 in animal models. At a dosage of 1 mg/kg, ICP-723 achieves a tumor growth inhibition rate (TGI) of 89.5% in the KM12 tumor model. With high oral bioavailability, ICP-723 demonstrates overall favorable pharmacokinetic parameters.
Next-Generation NTRK Inhibitor
ICP-723, a Chinese developed next-generation NTRK inhibitor, holds promise in treating advanced or metastatic solid tumors harboring NTRK fusion genes, including breast cancer, colorectal cancer, lung cancer, thyroid cancer, and patients resistant to first-generation NTRK inhibitors like larotrectinib and entrectinib.
On August 31, 2021, InnoCare Pharma announced the Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) to initiate Phase I clinical trials of its second-generation pan-TRK inhibitor ICP-723 in the United States.
In the major financial performance report released by InnoCare Pharma in 2022, the efficacy of ICP-723 was also disclosed.
Objective Response Rate (ORR)
As of February 11, 2022, in the Phase I dose-escalation trial, 17 patients received treatment with ICP-723 at doses ranging from 1 to 8 mg once daily. The safety profile was favorable, with no dose-limiting toxicities (DLT) observed. Among the 17 patients, 5 were confirmed positive for NTRK gene fusion, with an objective response rate (ORR) of 80%, including partial responses in 4 cases, and a disease control rate (DCR) of 100%. In the 4 mg and above dose group, the objective response rate was 100%.
As a novel small molecule second-generation pan-TRK inhibitor, ICP-723 exhibits potent activity and high selectivity, offering the potential to overcome resistance to first-generation TRK inhibitors and better serve patients.
(Note: This clinical trial is still recruiting participants. Patients who have undergone genetic testing can review their reports. Once NTRK1/2/3 fusion is detected, they can immediately contact us Advanced Medicine in China )
WhatsApp: +8613717959070
Email: doctor.huang@globecancer.com
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/02/202402261.png)
Precision Treatment Journey: Defeating Multiple Myeloma with Chinese CAR-T Therapy
👑🍋Precision Treatment Journey: Defeating Multiple Myeloma with Chinese CAR-T Therapy👑🍋
![Multiple Myeloma](https://www.medtourcn.com/wp-content/uploads/2024/02/202402261.png)
Multiple Myeloma
💪Meet John, a resilient man from New Zealand who has been battling multiple myeloma, a relentless form of cancer. Severe bone pain has confined him to bed for an extended period, disrupting his daily life. However, a glimmer of hope emerged when he sought treatment at Renji Hospital’s Hematology Department in Shanghai, China.
🍒Renji Hospital’s medical team, led by Professor Hou Jian, specializes in CAR-T cell therapy, a revolutionary approach to target cancer cells with precision. John’s journey began eleven years ago when he was diagnosed with multiple myeloma. Despite undergoing numerous chemotherapy sessions and two autologous stem cell transplants, his condition deteriorated rapidly over the past year.
🍈Intense back pain rendered him unable to stand or walk, forcing him into prolonged bed rest and heavy reliance on pain medication. Further assessments revealed widespread extramedullary plasmacytomas in his bones and throat, along with complex chromosomal abnormalities, indicating a grim prognosis.
🍓Having exhausted conventional treatments, John explored alternative options and learned about Renji Hospital’s expertise in CAR-T cell therapy for refractory multiple myeloma. In 2016, Professor Hou Jian’s team initiated clinical trials utilizing CAR-T cell therapy, accumulating significant experience in treating relapsed and refractory cases.
🍇Upon evaluation, John’s medical team identified substantial tumor burden and compromised bone marrow function due to extensive chemotherapy. Despite the challenges, Professor Hou Jian’s team tailored a personalized treatment plan, opting for dual CAR-T therapy targeting CD19 and BCMA antigens.
🥑John has since returned to New Zealand and maintains regular contact with his medical team at Renji Hospital. Ongoing monitoring and follow-ups ensure his progress is closely tracked. “John is gradually reclaiming his daily life. Recently, he even shared photos of hiking and fishing adventures with us,” Professor Hou Jian shared.
🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
Email: doctor.huang@globecancer.com,
WhatsApp: +8613717959070
#CARTtherapy #MultipleMyeloma #PrecisionTreatment #RenjiHospital #HopeInHealthcare #CART #cancer #cancertreatment #medicaltourism #tuomor #cartcell #CARTtherapy
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/02/202402130.png)
Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results!
🎉 Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results! 🚀
![Gastric Cancer, Pancreatic Cancer](https://www.medtourcn.com/wp-content/uploads/2024/02/202402130.png)
Gastric Cancer, Pancreatic Cancer
A burgeoning therapeutic target for gastric cancer—Claudin 18.2, its discovery has also opened a new chapter in targeted therapy for gastric cancer. If we talk about the hottest cell immunotherapy in recent years, it has to be chimeric antigen receptor T-cell (CAR-T) therapy. Based on this, Chinese researchers have developed the world’s first CAR-T cell therapy targeting Claudin18.2—CT041.
CT041, as the first CAR-T cell therapy targeting Claudin18.2, made its debut at the 2019 ASCO Annual Meeting. Among 12 patients with metastatic adenocarcinoma (7 gastric cancer, 5 pancreatic cancer) treated with Claudin18.2-targeting CAR T-cell therapy, no severe adverse events, treatment-related deaths, or serious neurotoxicity were reported. Among the 11 evaluated patients: 1 (gastric adenocarcinoma) achieved complete remission; 3 (2 gastric adenocarcinoma, 1 pancreatic adenocarcinoma) achieved partial remission; 5 had stable disease; and 2 experienced disease progression. The overall objective response rate was 33.3%.
At the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) held on January 19, 2024, SciGen showcased a clinical study of Claudin18.2-targeting autologous CAR-T cell therapy CT041 (satri-cel), reporting results from the dose escalation phase of the ELIMYN18.2 1b clinical trial conducted in the United States for the treatment of gastric/esophagogastric junction adenocarcinoma (GC/GEJ) or pancreatic cancer (PC).
This single-arm, open-label phase 1b/2 study primarily evaluated the safety and efficacy of CT041 in patients with advanced Claudin18.2-positive gastric/esophagogastric junction adenocarcinoma (GC/GEJ, progressing after at least second-line treatment or intolerant) or pancreatic cancer (PC, progressing after at least first-line treatment or intolerant).
Nineteen patients (9 GC/GEJ patients, 12 PC patients) received CT041 treatment at doses ranging from 250 to 600×106 cells: dose 1: 250-300×106 (n=6), dose 2: 375-400×106 (n=6), dose 3: 600×106 (n=7). All patients had received systemic therapy, with 85.7% of GC/GEJ patients and 58.3% of PC patients receiving ≥3 lines of systemic therapy. The median number of metastatic organs for all patients was 2, with at least one prior infusion. Clinical benefit rate included complete remission [CR], partial remission [PR], and stable disease [SD] ≥180 days.
As of September 15, 2023, with a median follow-up of 8.9 months, across all dose groups, the confirmed objective response rate (ORR) for gastric/esophagogastric junction adenocarcinoma patients was 42.9% (3/7); clinical benefit rate (CBR) was 57.1% (4/7); median progression-free survival (mPFS) and median duration of response (mDOR) were 5.7 months and 6.9 months, respectively. Additionally, the median overall survival (mOS) for gastric/esophagogastric junction adenocarcinoma or pancreatic cancer patients was 8.9 months. In dose level 3 (DL3), one gastric/esophagogastric junction adenocarcinoma patient achieved complete remission (CR). The clinical benefit rate for gastric/esophagogastric junction adenocarcinoma or pancreatic cancer patients was 71.4% (5/7), with a median OS of 12.9 months.
In summary, #CT041, as the first autologous #Claudin182 CAR-T cell therapy, demonstrates encouraging safety and shows promising preliminary efficacy in Claudin18.2-positive advanced GC/GEJ and PC patients who have received multiple prior treatments.
You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address: doctor.huang@globecancer.com, or click on the WhatsApp+8613717959070 icon on the homepage. The Medical Department will contact you as soon as they receive the reports.
🌟 #CART #Immunotherapy #CT041 #CancerResearch #ClinicalTrials #GastricCancer #PancreaticCancer #SciGen #ASCOGI2024
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/02/202402020.png)
Introducing China’s Top 10 Leading Cancer Hospitals!
🏥✨ Introducing China’s Top 10 Leading Cancer Hospitals! 🏥✨
![Top 10 Hospital](https://www.medtourcn.com/wp-content/uploads/2024/02/202402020.png)
Top 10 Hospital
1. Cancer Hospital, Chinese Academy of Medical Sciences 🍏🍏
http://www.cicams.ac.cn/
Located in Beijing, a Grade A tertiary hospital, China’s first specialized cancer hospital. It serves as the National Clinical Medical Research Center for Malignant Tumors, the National Standardized Diagnosis and Treatment Center for Tumors, the National Drug Clinical Research Center, the National Clinical Research Quality Evaluation and Promotion Center, and the location of the National Anticancer Drug Monitoring Network.
2.Sun Yat-sen University Cancer Center🍎🍎
https://www.sysucc.org.cn
Sun Yat-sen University Cancer Center (SYSUCC) is one of the four earliest tumor hospitals in China. It is one of the affiliated hospitals of the prestigious Sun Yat-sen University. Located in the city of Guangzhou, SYSUCC is leading the way on a national frontier. It is the largest integrated cancer center in the whole of southern China for cancer . SYSUCC’s mission is to help people prevent and cure cancer.
3.Shanghai Cancer Center🍐🍐
https://www.shca.org.cn/
The Fudan University Shanghai Cancer Center (FUSCC), also called the Shanghai Cancer Hospital, is a teaching hospital affiliated with the Shanghai Medical College of Fudan University. Founded in 1931, it is the first cancer specialty hospital in China. It is rated Grade 3, Class A.
4.Peking University Cancer Hospital 🍊🍊
https://www.bjcancer.org/
Peking University Cancer Hospital (three other titles — Beijing Cancer Hospital, Beijing Institute for Cancer Research, and Peking University School of Oncology — refer to the same entity) ranks among the China’s top academic cancer centers。Peking University Cancer Hospital physicians provide patient-oriented medical services in a wide variety of cancer specialties treating gastric cancer, breast cancer, lung cancer, colorectal cancer, liver cancer, esophageal carcinoma, lymphoma, melanoma, and much more. Our team consists of a group of experts from different disciplines including oncology (cancer medicine), surgeons, radiology, and pathology.
5. Tianjin Medical University Cancer Institute & Hospital 🍋🍋
http://www.tjmuch.com/
Tianjin Medical University Cancer Institute & Hospital (TMUCIH) is one of the largest specialized hospitals in China with integrated patient care, education, training, research and preventative medicine. In 2013, TMUCIH was designated as National Clinical Research Center for Cancer by the Ministry of Science and Technology of The People’s Republic of China. In 2017, Oncology was selected as the National “World-Class” Academic Development Program in Tianjin Medical University by the Ministry of Education, the Ministry of Finance, and the National Development and Reform Commission.
The most recognized specialties in the hospital are basic and clinical research on breast cancer, lung cancer, esophageal cancer, liver cancer, head & neck cancer, biotherapy, molecular imaging, radiation oncology, medical oncology, pathology as well as epidemiology.
6. ShanDong Cancer Hospital 🍒🍒
http://www.sd-cancer.com/
Shandong First Medical University Affiliated Cancer Hospital, located in Jinan, is designated as a national clinical key specialty construction unit in oncology, a participant in the national project to enhance the diagnosis and treatment capabilities of difficult diseases, a national drug clinical trial institution, and the Chair of the Chinese Society of Clinical Oncology (a national first-level association). It serves as the Chairman Unit of the Radiotherapy Branch of the Chinese Medical Association, a clinical medicine center in Shandong Province, the Cancer Center of Shandong Province, the Tumor Quality Control Center of Shandong Province, the Anti-Cancer Association of Shandong Province, the Clinical Oncology Society of Shandong Province, and is affiliated with the Cancer Prevention and Control Office of Shandong Province.
7. West China Hospital🍉🍉
https://wcums.scu.edu.cn/
West China Hospital of Sichuan University is a national-level center for the diagnosis and treatment of difficult and critical illnesses in western China. It is also the world’s largest comprehensive single-point hospital and boasts the largest and earliest medical testing center in China to be accredited by the College of American Pathologists (CAP). It has been designated by the National Health Commission as one of the first pilot hospitals for multidisciplinary diagnosis and treatment of tumors.
8. Zhejiang Cancer Hospital 🍇🍇
https://www.zchospital.com/
Founded in October 1963, Zhejiang Cancer Hospital (ZJCH) is one of the earliest four cancer specialized hospitals in China to maintain the highest standards of excellence in patient care, cancer prevention, research, education and rehabilitation and is ranked among the Top 10 Best Cancer Hospitals of China for 8 consecutive years. The hospital is ranked third in cancer hospitals of China for performance assessment of national public hospital, which is first published in 2020.
9. Jiangsu Cancer Hospital🍓🍓
https://www.jszlyy.com.cn/
Jiangsu Cancer Hospital, located in Hangzhou, is a Grade A tertiary specialized hospital for oncology. It serves as a teaching center for cancer prevention, treatment, and research, as well as for scientific research and education in Jiangsu Province. It has been designated by the National Health Commission as one of the first pilot hospitals for multidisciplinary diagnosis and treatment of tumors.
Jiangsu Cancer Hospital is State Institution of Drug Clinical Trials, the first batch of National Standardized Training Base for Resident Physicians and Standardized Cancer Pain Treatment Demonstration Ward announced by the Ministry of Health, Guidance Hospital for Standardized Treatment of Malignant Tumors in Municipalities
10. Sichuan Cancer Hospital & Institute🍈🍈
https://www.sichuancancer.org/
Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliate Cancer Hospital Of University Of Electronic Science and Technology of China (UESTC) ,Which is The Largest National Tertiary Level Class A Cancer Hospital In Southwest China for Cancer Prevention, Treatment, Rehabilitation, Research and Education, was Established in 1979 .
As A First Class Cancer Hospital In Southwest, Sichuan Cancer Hospital Has Characteristics and Advantages in the Comprehensive Treatment of Lung Cancer, Esophageal Cancer, Breast Cancer, Colorectal Cancer, Primary Liver Cancer, Malignant Lymphoma, Head And Neck Cancer, And Gynecological Cancer. Thriving from The Dominant Discipline Of Radiotherapy, Sichuan Cancer Hospital Has Built the Biggest Brachytherapy Center In Western China.
Stay tuned for more updates on China’s leading cancer hospitals!
🌸In addition to lung cancer, we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!
🧶You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:
🌈🌈📩doctor.huang@globecancer.com🌈🌈, or click on the ☎️WhatsApp+8613717959070☎️ .
The Medical Department will contact you as soon as they receive the reports.
#TopCancerHospitals #CancerCare #MedicalExcellence #chinesehospital #Tophospital #cancerhospital #top10hospital
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/01/202401230.png)
China’s Breakthrough: Sunvozertinib Leads the Wave of New Drug Development in EGFR exon20ins Mutant NSCLC
🌈🌈China’s Breakthrough: Sunvozertinib Leads the Wave of New Drug Development in EGFR exon20ins Mutant NSCLC🌸🌸
**Caption:**
🇨🇳 Exciting news from China’s research! Sunvozertinib, a novel drug by Dizal Pharmaceuticals, is making strides in treating EGFR exon20ins mutant NSCLC. 🌐✨
![Sunvozertinib](https://www.medtourcn.com/wp-content/uploads/2024/01/202401230.png)
Sunvozertinib
**Article:**
Dizal Pharmaceuticals’ EGFR tyrosine kinase inhibitor (TKI) Sunvozertinib, known as 舒沃替尼 (Shuwo Tini) in China, has achieved a significant milestone with the publication of data from its Chinese registration study (WU-KONG6) in “The Lancet Respiratory Medicine.” This study validates the clinical efficacy of the Chinese-developed drug in treating late-stage non-small cell lung cancer (NSCLC) with EGFR exon20ins mutations, marking a crucial breakthrough for patients who have long faced challenges in finding effective treatments.
**Challenges in Treating EGFR exon20ins Mutant NSCLC**
EGFR exon20ins mutation has been a formidable subtype in EGFR-mutant NSCLC, with limited effectiveness observed in traditional EGFR-TKI and chemotherapy treatments. Faced with this challenge, pharmaceutical companies are actively engaged in new drug development to propel advancements in the treatment landscape for EGFR exon20ins mutant NSCLC. The success of the WU-KONG6 study signifies a critical recognition in this field and affirms the high efficacy and low toxicity of Sunvozertinib in treating EGFR exon20i
![Lancet](https://www.medtourcn.com/wp-content/uploads/2024/01/202401231.png)
Lancet
ns mutant NSCLC.
**Results from the Chinese Registration Study “WU-KONG6″**
The results of the Chinese registration study “WU-KONG6” demonstrate that Sunvozertinib achieved an objective response rate (ORR) of 60.8% in treated patients with EGFR exon20ins mutations. This indicates a significant tumor reduction in over 60% of patients, leading to a substantial decrease in tumor burden. Moreover, patients experienced improvements in clinical symptoms and quality of life. Notably, Sunvozertinib is currently the only drug that has elevated the ORR in treated patients with EGFR exon20ins mutations to over 50%, breaking previous treatment ceilings and showcasing its potential as the “best in class.”
**Looking Ahead**
The competition in the field of EGFR exon20ins mutant NSCLC treatment is intensifying, and the successful introduction of Sunvozertinib provides a new therapeutic option for patients. As other pharmaceutical companies globally advance in new drug development, the innovation and competition in this field are expected to escalate, bringing more hope to patients with EGFR exon20ins mutant NSCLC. In the continual pursuit of medical breakthroughs, the emergence of new drugs will offer more effective treatment options, contributing to the extension of patients’ survival periods.
#MedicalInnovation #CancerResearch #HopeForPatients #Sunvozertinib #MedicalBreakthrough #ChinaInnovation
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/01/202401220.png)
Revolutionizing Medicine: CAR-T Therapy Beyond Cancer
🚀Revolutionizing Medicine: CAR-T Therapy Beyond Cancer 🚀
![](https://www.medtourcn.com/wp-content/uploads/2024/01/202401220.png)
🔬 Over the past decade, CAR-T cell therapy has transformed the field of oncology, successfully treating previously incurable blood cancers. While CAR-T therapy gained fame for its success in cancer treatment, the roots of this groundbreaking principle trace back nearly 30 years—initially exploring T cell therapy for HIV/AIDS. Although the early attempts didn’t succeed in treating HIV/AIDS, they demonstrated the enduring potential of engineered T cells in immunocompromised patients.
🌟 CAR-T therapy, or Chimeric Antigen Receptor T-cell Immunotherapy, essentially involves reengineering a patient’s immune T cells outside the body to recognize antigens on the surface of tumor cells. These modified cells are then reintroduced into the patient, effectively identifying and eliminating cancer cells. Scientists have been tirelessly working to extend CAR-T therapy beyond blood cancers to various other types.
💡 Moreover, research from both clinical and preclinical studies indicates that CAR-T therapy holds great promise beyond cancer treatment. It shows potential applications in autoimmune diseases, chronic infections, heart diseases, aging-related conditions, and more.
🌐 In recent years, scientists have focused on applying CAR-T therapy to solid tumors, exploring its potential in cancer types beyond blood-related malignancies. Early research results suggest that the next frontier for CAR-T therapy may extend to various fields outside cancer, including autoimmune diseases (systemic lupus erythematosus, pemphigus vulgaris, multiple sclerosis, type 1 diabetes, asthma), fibrotic diseases (fibrosis in the heart, liver, lungs, and kidneys), aging-related conditions (liver fibrosis, solid tumors, atherosclerosis, natural aging), and infectious diseases (HIV/AIDS, hepatitis B and C, pulmonary tuberculosis).
🚀 The future of CAR-T therapy holds vast potential in reshaping the landscape of medical treatment, reaching far beyond the realms of cancer. Stay tuned for ground
#immunotherapyrevolution #CARTTherapy #MedicalInnovation #BeyondCancer #ImmunotherapyRevolution #CART #cancer #tumor #cancertreatment #tcell
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/01/202401190.jpg)
Exciting breakthrough in Chinese pharmaceutical research!
[🔬🌏] Exciting breakthrough in Chinese pharmaceutical research!
![Chinese medicial research](https://www.medtourcn.com/wp-content/uploads/2024/01/202401190.jpg)
Chinese medicial research
💊Since 2019, China has witnessed a surge in phase 1 and 2 clinical trials, with a focus on addressing prevalent cancers like stomach, esophageal, and cervical cancers. The world is now turning its attention to China’s rapid emergence on the global stage of pharmaceutical innovation.
🌟 Key Highlights:
PD-1, PD-L1, VEGFR, EGFR, and HER2 are at the forefront of Chinese drug development.
PD-1/PD-L1 therapies have shown outstanding efficacy in Asian patients, gaining approvals for various cancer treatments. The influx of these therapies has increased accessibility to cancer immunotherapy, simultaneously driving market competition and reducing economic burdens for patients and healthcare systems.
🚀 2020 and Beyond:
Rapid growth in the development of VEGFR, EGFR, and HER2 pathways. The approval of AK104, a dual-specificity PD-1/CTLA-4 antibody for cervical cancer treatment, marks a milestone.
Innovative discoveries in clinical research for gastrointestinal tumor drug targets like CLDN18.2, including CLDN18.2–CD3, CLDN18.2–PD-L1, and CLDN18.2 antibody-drug conjugates, promise a bright future for cancer treatments.
🌿 Traditional Medicine Meets Innovation:
Local biopharmaceutical companies in China are shifting towards “First in Class.” FDA and NMPA approvals for novel drugs like PRJ1-3024, ORIN001, and JS004 showcase this shift.
Traditional Chinese Medicine (TCM) continues to play a vital role in oncology, with formulations like As2O3 displaying potent anti-tumor activity. TCM is gaining attention, actively researching and revealing its anti-cancer mechanisms.
🔍 Future of Cellular Therapy:
While most studies focus on hematologic cancers, China’s research on solid tumor cellular therapy is rapidly expanding.
Diverse targets in solid tumors (gastric, lung, and neural) include MSLN, GPC3, MUC1, and CLDN18.2.
China’s forefront research in cellular therapy faces challenges but remains promising. With more efforts and innovations, the hope is for more effective solid tumor treatments in the future.
🌐 #ChinaMedicalInnovation #DrugDevelopment #CancerTreatment #CellularTherapy #medicalresearch
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
![image](https://www.medtourcn.com/wp-content/uploads/2024/01/202401180.jpg)
China Leading Global Advances in Breast Cancer Immunotherapy
🌟China Leading Global Advances in Breast Cancer Immunotherapy 🌟#ChinaInMedicine #BreastCancer
![Breast Cancer](https://www.medtourcn.com/wp-content/uploads/2024/01/202401180.jpg)
Breast Cancer
Since 2020, breast cancer has surpassed lung cancer, becoming the most common cancer globally with approximately 2.3 million new cases and 680,000 deaths annually. Despite improvements in traditional treatments like surgery, chemotherapy, and radiation, the mortality rate remains high. China’s Chimeric Antigen Receptor (CAR) immunotherapy is making significant strides, spearheading innovation in breast cancer treatment. 🇨🇳💪
Recent studies indicate substantial breakthroughs in CAR-T therapy, as well as CAR-NK cells and CAR macrophages for breast cancer treatment. The application of combination therapies further enhances the cytotoxicity of CAR-based cell therapies against breast cancer cells, bringing new hope to patients. 🚀
China is at the forefront of global clinical research on CAR, with 16 clinical trials focused on CAR-T or CAR-NK cell therapies currently underway. Particularly noteworthy is the research at the People’s Liberation Army General Hospital, where CAR-T cells targeting CD133 are employed to treat refractory advanced malignant tumors, including breast cancer. This approach has demonstrated excellent anti-tumor activity and manageable safety in patients previously treated for advanced hepatocellular carcinoma and cholangiocarcinoma. 🏥✨
On another front, the clinical study at Sun Yat-sen Memorial Hospital, Zhongshan University, is equally intriguing. They are exploring PD-1 knockout CAR-T cells targeting MUC1 for treating late-stage breast cancer patients. This trial is a dose-escalation exploratory study, and researchers anticipate its results to pave the way for future treatments. 🧪🔍
China is not only a trailblazer in breast cancer immunotherapy research but also a miracle creator, bringing new hope to cancer patients worldwide. Let’s witness China’s outstanding achievements in the medical field and acknowledge its contribution to global health! 💊🌏
![](https://www.medtourcn.com/wp-content/uploads/2024/01/202401181.jpg)
#ImmunotherapyAdvancements #BreastCancerResearch